A phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK’s meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults
Participants needed: 16-17
Meningococcal disease is caused by the bacteria Neisseria meningitidis and can result in very severe disease such as sepsis (blood infection) and meningitis. There are currently vaccines that protect against 4 different types (A, C, W, Y) being used across Canada and doctors want to protect against type B too
Healthy 16- 17 year olds who are have not received a Men ACWY Vaccination in the last 4 years.
What is involved
Participants will receive a MenACWY + B vaccine. There will be 6 visits to the study clinic and 7 phone calls over the course of 12 months. These visits will include a physical exam, vaccinations, blood tests, and questions about your health. . You will receive: Eligible participants will be reimbursed for travel/parking & receive a gift card at each visit.
Before any study activities are performed, you and your parent/guardian will be asked to review and sign the consent form .